Climb Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CLYM Nasdaq 2836 climbbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Climb Bio, Inc.

Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026 - May 26th, 2026 5:00 am
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect - May 20th, 2026 11:02 pm
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress - May 14th, 2026 5:00 am
Climb Bio to Present at Upcoming Investor Conferences - May 12th, 2026 5:00 am
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates - May 7th, 2026 5:00 am
Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE - May 5th, 2026 1:27 pm
Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing - May 5th, 2026 11:05 am
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts - May 5th, 2026 5:00 am
Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026 - May 1st, 2026 2:17 am
Climb Bio (CLYM) Receives FDA Fast Track Designation for Budoprutug in Rare Kidney Disease - Apr 29th, 2026 11:00 am
Climb Bio, Inc. Announces $110.0 Million Private Placement - Apr 28th, 2026 5:00 am
FDA Fast Track and a BTIG Buy; Is Climb Bio (CLYM) a Must-Buy Small Cap Stock? - Apr 20th, 2026 8:48 am
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 - Apr 8th, 2026 5:00 am
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy - Apr 7th, 2026 5:00 am
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - Apr 6th, 2026 11:00 am
Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026 - Mar 14th, 2026 6:03 am
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Mar 5th, 2026 5:00 am
Climb Bio Highlights 2025 Data Catalysts, CD19 and APRIL Programs at Oppenheimer Conference - Feb 26th, 2026 12:11 am
Climb Bio Teases 5 Data Readouts in 2026, Highlights CD19 and APRIL “Sweeper” Programs at Summit - Feb 13th, 2026 1:07 am
Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value Estimate - Jan 24th, 2026 7:18 am